Mitochondrial oxidative phosphorylation (OxPhos) induces resistance to MAPK pathway inhibitors in melanoma. However, therapeutic targeting of mitochondria is challenging. In a recent study, we showed that inhibition of mTOR kinase activity resensitized resistant melanomas by indirectly inhibiting OxPhos via a novel mechanism. Here, we discuss the implications of these findings.
In the 1920s Otto Warburg observed that, unlike normal cells, cancer cells exhibit aerobic glycolysis, i.e., a high rate of glycolysis even in the presence of oxygen. Initially postulated to be the result of mitochondrial dysfunction, it is now recognized that the Warburg effect is a metabolic adaptation in cells with intact mitochondria that is driven by microenvironmental factors or by mutations in classical signaling pathways. For example, mitochondrial respiration in low-oxygen environments produces reactive oxygen species (ROS) and induces oxidative stress. This promotes HIF1a stabilization, which then shifts cellular metabolism toward glycolysis by inactivating pyruvate kinase. However, HIF1a can also be stabilized under normoxic conditions via facilitative gene mutations or by activation of signaling pathways such as PI3K-AKT. Moreover, it has now been demonstrated that tumors employ a variety of metabolic adaptations beyond aerobic glycolysis, including altered glutamine metabolism. Although classic inhibitors of mitochondrial respiration are too toxic for clinical implementation some researchers have proposed biguanides such as metformin or phenformin as potential candidates; however, their non-specificity and dosage requirements may limit their use for cancer therapy. 5 We recently used 2 unbiased approaches-whole genome siRNA synthetic lethality screening and mRNA expression profiling-to broadly interrogate melanoma resistance to MAPKi and identified elevated OxPhos as a key mediator of resistance. 6 Similar to other recent studies, we found that elevated OxPhos significantly correlated with expression of PGC1a and MITF. 2, 3 In addition to confirming the role of OxPhos in de novo resistance, we demonstrated for the first time that, in approximately half of all examined melanoma cell lines and patient samples with acquired resistance, MAPKi resistance was associated with high OxPhos and high PGC1a. 6 We had previously observed that some cell lines with de novo resistance to MAPKi were sensitive to a combination of the MEK inhibitor Selumetinib (MEKi) and the catalytic mTOR inhibitor AZD8055 (mTORC1/ 2i), which inhibits both Raptor and Rictor complexes of mTOR. 7 In the current study, we unexpectedly found that combination treatment with MEKi and mTORC1/2i resulted in synergistic growth inhibition and apoptosis of BRAF V600E -mutant and NRAS-mutant de novo MAPKi-resistant cell lines with high OxPhos/PCG1a. However, this synergy was not observed in resistant lines with low OxPhos/PGC1a. In addition to its efficacy in de novo resistance, this combination was also effective in melanomas with acquired MAPKi resistance that had high OxPhos/PGC1a, but was ineffective in those with low OxPhos/PGC1a. In a BRAF V600E -mutant high OxPhos/PGC1a xenograft mouse model, this combination was significantly more effective in suppressing tumor growth than either inhibitor alone. Although mTORC1 has previously been implicated in mitochondrial activation, 8, 9 we demonstrated for the first time that inhibition of both mTORC1 and mTORC2 decreases OxPhos more effectively than inhibition of either complex alone. Furthermore, we found that mTORC1/2i markedly reduces PGC1a expression by decreasing nuclear levels of its key transcriptional activator, MITF. Although we did not evaluate its mechanism of action, we hypothesize that mTOR activity enhances nuclear MITF levels by preventing its cytoplasmic extrusion and/or degradation; MITF nuclear levels are further increased by MAPKi-induced nuclear localization and de novo expression, which in turn transcriptionally activates PGC1a (Fig. 1A and B) . Conversely, mTOR1/2i treatment promotes cytoplasmic extrusion and/or degradation of MITF, thus decreasing its nuclear levels and the level of PGC1a (Fig. 1C) . Elucidation of this mechanism may benefit the development of therapeutic agents.
Although our study has emphasized the significance of high OxPhos in MAPKi resistance, this metabolic phenotype was not universal among resistant cell lines or patient samples. Cell lines that demonstrated low OxPhos/PGC1a were not sensitive to the combination of MEKi plus mTORC1/2i. We did not identify the mechanism of resistance of the low OxPhos MAPKi resistant cell lines, but a recent study by Parmenter et al. described a network of transcription factors including HIF1a and MYC that were downregulated in melanoma cell lines and patient samples in response to MAPKi, resulting in inhibition of glycolysis. 10 Although no alterations in OxPhos levels were observed, glycolysis and its associated transcriptional networks were restored in cells and samples from patients that developed resistance.
In summary, recent work has shown that oncogenic signaling pathways can drive metabolic reprogramming in melanoma, and that metabolic adaptation is a mechanism of resistance to targeted therapy. However, there is also heterogeneity of metabolic phenotypes, which appears to drive the response to combinatorial therapy. Specifically, we and others have demonstrated that OxPhos is a major mechanism of both de novo and acquired resistance to MAPKi in melanoma and that this is driven by increased expression of MITF and PCG1a. We have also demonstrated that MAPKi resistance can be overcome by mTORC1/2i acting via nuclear exclusion of MITF, and that this combination is synergistic only in the high OxPhos phenotype. These findings support the rationale for the identification of clinical biomarkers to identify targetable metabolic adaptations such as OxPhos in melanoma and other cancers and thus counteract resistance to targeted therapies.
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